Insider Ledger
AGIO insider buying and SEC filings, explained
Agios Pharmaceuticals, Inc. · CIK 1439222
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- AGIOS PHARMACEUTICALS INC
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$152K
Planned sales (10b5-1)
$4.8M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 26, 2026 | Planned (10b5-1) | Sarah Gheuens (Chief Medical Officer) sold 7,866 shares at about $37.69 ($296K), marked as a 10b5-1 plan trade. Holdings down 13% to 54,645 shares. | SEC filing Filed Oct 28, 2026, 4:02 PM ET |
| Oct 21–22, 2026 | Planned (10b5-1) | Sarah Gheuens (Chief Medical Officer) sold 1,989 shares between Oct 21 and Oct 22 at about $37.53 ($75K), marked as a 10b5-1 plan trade. Holdings down 4% to 54,645 shares. | SEC filing Filed Oct 23, 2026, 4:05 PM ET |
| Aug 4, 2026 | Planned (10b5-1) | Sarah Gheuens (Chief Medical Officer) sold 30,000 shares at about $30.48 ($914K), marked as a 10b5-1 plan trade. Holdings down 35% to 54,645 shares. | SEC filing Filed Aug 6, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Sarah Gheuens (Chief Medical Officer) sold 4,007 shares at $37.56 ($151K), marked as a 10b5-1 plan trade. Holdings down 5% to 84,645 shares. | SEC filing Filed Jul 2, 2026 |
| Apr 2, 2026 | Planned (10b5-1) | James William Burns (Chief Legal Officer) sold 3,280 shares at $34.71 ($114K), marked as a 10b5-1 plan trade. Holdings down 6% to 49,306 shares. | SEC filing Filed Apr 6, 2026 |
| Apr 2, 2026 | Planned (10b5-1) | Sarah Gheuens (Chief Medical Officer) sold 2,940 shares at $34.71 ($102K), marked as a 10b5-1 plan trade. Holdings down 4% to 80,277 shares. | SEC filing Filed Apr 6, 2026 |
| Apr 2, 2026 | Planned (10b5-1) | Cecilia Jones (CFO) sold 3,141 shares at $34.71 ($109K), marked as a 10b5-1 plan trade. Holdings down 5% to 54,998 shares. | SEC filing Filed Apr 6, 2026 |
| Apr 2, 2026 | Planned (10b5-1) | Tsveta Milanova (Chief Commercial Officer) sold 3,262 shares at $34.71 ($113K), marked as a 10b5-1 plan trade. Holdings down 7% to 46,829 shares. | SEC filing Filed Apr 6, 2026 |
| Apr 2, 2026 | Planned (10b5-1) | Krishnan Viswanadhan (Chief Corp Dev & Strategy) sold 2,959 shares at $34.71 ($103K), marked as a 10b5-1 plan trade. Holdings down 22% to 10,282 shares. | SEC filing Filed Apr 6, 2026 |
| Apr 2, 2026 | Planned (10b5-1) | Brian Goff (CEO and Director) sold 19,068 shares at $34.71 ($662K), marked as a 10b5-1 plan trade. Holdings down 9% to 184,508 shares. | SEC filing Filed Apr 6, 2026 |
| Mar 5, 2026 | Planned (10b5-1) | Krishnan Viswanadhan (Chief Corp Dev & Strategy) sold 2,959 shares at $27.80 ($82K), marked as a 10b5-1 plan trade. Holdings down 37% to 5,141 shares. | SEC filing Filed Mar 9, 2026 |
| Mar 3, 2026 | Sale | Theodore James Washburn Jr. (Principal Accounting Officer) sold 5,272 shares at $28.88 ($152K). Holdings down 86% to 868 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 5, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Brian Goff (CEO and Director) sold 18,055 shares at $28.96 ($523K), marked as a 10b5-1 plan trade. Holdings down 10% to 164,548 shares. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | James William Burns (Chief Legal Officer) sold 5,218 shares at $28.96 ($151K), marked as a 10b5-1 plan trade. Holdings down 11% to 44,086 shares. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Sarah Gheuens (Chief Medical Officer) sold 4,055 shares at $28.96 ($117K), marked as a 10b5-1 plan trade. Holdings down 5% to 74,406 shares. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Cecilia Jones (CFO) sold 5,035 shares at $28.96 ($146K), marked as a 10b5-1 plan trade. Holdings down 9% to 49,328 shares. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Tsveta Milanova (Chief Commercial Officer) sold 2,868 shares at $28.96 ($83K), marked as a 10b5-1 plan trade. Holdings down 6% to 41,591 shares. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Theodore James Washburn Jr. (Principal Accounting Officer) sold 2,223 shares at $28.96 ($64K), marked as a 10b5-1 plan trade. Holdings down 27% to 6,140 shares. | SEC filing Filed Mar 3, 2026 |
| Jan 5, 2026 | Planned (10b5-1) | Tsveta Milanova (Chief Commercial Officer) sold 2,872 shares at $27.02 ($78K), marked as a 10b5-1 plan trade. Holdings down 8% to 34,793 shares. | SEC filing Filed Jan 7, 2026 |
| Dec 30, 2025 | Planned (10b5-1) | James William Burns (Chief Legal Officer) sold 2,932 shares at $27.09 ($79K), marked as a 10b5-1 plan trade. Holdings down 8% to 31,718 shares. | SEC filing Filed Jan 2, 2026 |
| Dec 30, 2025 | Planned (10b5-1) | Brian Goff (CEO and Director) sold 18,703 shares at $27.09 ($507K), marked as a 10b5-1 plan trade. Holdings down 12% to 143,103 shares. | SEC filing Filed Jan 2, 2026 |
| Dec 30, 2025 | Planned (10b5-1) | Sarah Gheuens (Chief Medical Officer) sold 2,932 shares at $27.09 ($79K), marked as a 10b5-1 plan trade. Holdings down 4% to 64,795 shares. | SEC filing Filed Jan 2, 2026 |
| Dec 30, 2025 | Planned (10b5-1) | Tsveta Milanova (Chief Commercial Officer) sold 2,932 shares at $27.09 ($79K), marked as a 10b5-1 plan trade. Holdings down 9% to 29,190 shares. | SEC filing Filed Jan 2, 2026 |
| Dec 30, 2025 | Planned (10b5-1) | Cecilia Jones (CFO) sold 2,932 shares at $27.09 ($79K), marked as a 10b5-1 plan trade. Holdings down 7% to 37,394 shares. | SEC filing Filed Jan 2, 2026 |
| Nov 12, 2025 | Planned (10b5-1) | David Scadden (Director) sold 200 shares at $43.84 ($9K), marked as a 10b5-1 plan trade. Holdings down 1% to 17,603 shares. | SEC filing Filed Nov 14, 2025 |
| Nov 11, 2025 | Planned (10b5-1) | Sarah Gheuens (Chief Medical Officer) sold 2,454 shares at about $43.78 ($107K), marked as a 10b5-1 plan trade. Holdings down 4% to 61,727 shares. | SEC filing Filed Nov 13, 2025 |
43 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow AGIO in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.